PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace’s commercial efforts and play a pivotal role in driving the Company’s next phase of rapid innovation, strategic product commercialization, and growth. “I am thrilled to welcome Guy to the Treace team,” said John T. Treace, CEO, Founder and Board Member of Treace. “With a wealth of diverse medical technology industry experience, a demonstrated track record of strong customer engagement, leadership in innovation and product development, and a proven ability to deliver exceptional market growth, Guy is ideally suited to lead our commercial efforts.” “I’ve always admired and respected Treace, having watched the team create and lead in entirely new market segments,” said Mr. Guglielmino. “Treace has established a new standard with an approach that deeply understands their customers’ unmet needs, resulting in groundbreaking innovations that democratize the practice of the surgical treatment of bunions and midfoot deformities. I look forward to working with John and the Treace leadership team to deliver class-leading innovation, product commercialization, and sustained market performance.” Mr. Guglielmino joins Treace with deep medical technology industry expertise, having served in diverse senior leadership roles. Most recently, Mr. Guglielmino was President, Recovery Sciences at Enovis. Prior to that, he held senior Marketing roles at Enovis, Wright Medical, and at Bausch + Lomb. Mr. Guglielmino received his Bachelor of Science in Business & Entrepreneurship and his MBA from the Rochester Institute of Technology. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s expectations of innovation, product commercialization, market performance, and growth. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. Internet Posting of Information Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com . The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace. About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlateTM Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com . To learn more about Treace, connect with us on LinkedIn , X , Facebook and Instagram . Contacts : Treace Medical Concepts Mark L. Hair Chief Financial Officer mhair@treace.net (904) 373-5940 Investors : Gilmartin Group Vivian Cervantes IR@treace.net50jili app apk 。

Caprock Group LLC trimmed its position in shares of Qualys, Inc. ( NASDAQ:QLYS – Free Report ) by 5.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,878 shares of the software maker’s stock after selling 178 shares during the quarter. Caprock Group LLC’s holdings in Qualys were worth $370,000 at the end of the most recent reporting period. A number of other institutional investors have also modified their holdings of the company. Financial Enhancement Group LLC lifted its position in Qualys by 1.5% during the third quarter. Financial Enhancement Group LLC now owns 6,100 shares of the software maker’s stock valued at $784,000 after acquiring an additional 91 shares during the last quarter. Bank of Montreal Can increased its position in shares of Qualys by 2.2% during the second quarter. Bank of Montreal Can now owns 4,896 shares of the software maker’s stock worth $699,000 after purchasing an additional 107 shares in the last quarter. Legacy Advisors LLC lifted its holdings in shares of Qualys by 1.4% during the 2nd quarter. Legacy Advisors LLC now owns 8,272 shares of the software maker’s stock valued at $1,180,000 after purchasing an additional 113 shares during the last quarter. Advisors Asset Management Inc. boosted its position in shares of Qualys by 8.1% in the 1st quarter. Advisors Asset Management Inc. now owns 1,684 shares of the software maker’s stock worth $281,000 after purchasing an additional 126 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Qualys by 0.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 46,436 shares of the software maker’s stock worth $6,622,000 after buying an additional 127 shares during the last quarter. 99.31% of the stock is currently owned by institutional investors. Analyst Upgrades and Downgrades QLYS has been the subject of a number of research analyst reports. Royal Bank of Canada increased their price target on Qualys from $150.00 to $162.00 and gave the company a “sector perform” rating in a research note on Wednesday, November 6th. Needham & Company LLC started coverage on shares of Qualys in a research report on Wednesday, November 6th. They issued a “hold” rating for the company. Morgan Stanley lifted their target price on shares of Qualys from $123.00 to $126.00 and gave the stock an “underweight” rating in a research note on Wednesday, November 6th. Truist Financial upped their price target on shares of Qualys from $120.00 to $145.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Finally, Canaccord Genuity Group lifted their price objective on shares of Qualys from $160.00 to $170.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Three research analysts have rated the stock with a sell rating, fourteen have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $152.80. Qualys Stock Up 2.1 % Shares of QLYS opened at $153.37 on Friday. The stock’s 50-day moving average price is $131.26 and its 200-day moving average price is $135.03. The company has a market capitalization of $5.61 billion, a price-to-earnings ratio of 33.78 and a beta of 0.47. Qualys, Inc. has a 52 week low of $119.17 and a 52 week high of $206.35. Qualys ( NASDAQ:QLYS – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 5th. The software maker reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.23. Qualys had a net margin of 28.72% and a return on equity of 40.24%. The business had revenue of $153.87 million for the quarter, compared to analysts’ expectations of $150.74 million. During the same quarter last year, the company earned $1.24 EPS. The business’s revenue was up 8.4% on a year-over-year basis. As a group, equities analysts anticipate that Qualys, Inc. will post 4.34 EPS for the current fiscal year. Insider Buying and Selling at Qualys In other news, insider Bruce K. Posey sold 1,330 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $123.80, for a total transaction of $164,654.00. Following the sale, the insider now directly owns 55,618 shares in the company, valued at $6,885,508.40. This trade represents a 2.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website . Also, Director Jeffrey P. Hank sold 4,000 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $146.31, for a total value of $585,240.00. Following the completion of the transaction, the director now directly owns 12,666 shares of the company’s stock, valued at $1,853,162.46. The trade was a 24.00 % decrease in their position. The disclosure for this sale can be found here . Over the last quarter, insiders sold 21,919 shares of company stock valued at $2,993,000. Corporate insiders own 1.00% of the company’s stock. Qualys Company Profile ( Free Report ) Qualys, Inc, together with its subsidiaries, provides cloud-based platform delivering information technology (IT), security, and compliance solutions in the United States and internationally. It offers Qualys Cloud Apps, which include Cybersecurity Asset Management and External Attack Surface Management; Vulnerability Management, Detection and Response; Web Application Scanning; Patch Management; Custom Assessment and Remediation; Multi-Vector Endpoint Detection and Response; Context Extended Detection and Response; Policy Compliance; File Integrity Monitoring; and Qualys TotalCloud, as well as Cloud Workload Protection, Cloud Detection and Response, Cloud Security Posture Management, Infrastructure as Code, and Container Security. Further Reading Receive News & Ratings for Qualys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualys and related companies with MarketBeat.com's FREE daily email newsletter .Kansas City Chiefs back to winning ways against Carolina Panthers

NHL fines Edmonton Oilers forward Jeff Skinner $2,000 for embellishmentHigh-End Bicycle Market to Grow by USD 5.03 Billion (2024-2028), Driven by E-Bike Adoption in Developing Countries, with AI Impacting Market Trends - Technavio

NoneA 4.45 billion-year-old zircon grain, extracted from a Martian meteorite, that was found in the Sahara in 2011, has revealed new details about the Red Planet's past. The study, conducted by researchers from Perth's Curtin University, indicates that Mars once had boiling hydrothermal systems like Earth's volcanoes. This also means that the planet may have been habitable at some point in its history and could have supported microbial life. 'Black Beauty' meteorite offers unique insights The research team analyzed meteorites from a space rock named NWA7034, or 'Black Beauty.' Unlike most Martian meteorites, which are mostly igneous or mantle rocks, these offer unique insights into Mars's geological history. Aaron Cavosie, a planetary scientist from Curtin University's Space Science and Technology Centre in Australia, said Black Beauty is unique as it is a regolith sample from Mars's surface and contains hundreds of rock and mineral fragments from different sources across the planet. Zircon grain analysis reveals hot water on Mars About 20 meteorites discovered on Earth are thought to have come from Mars during the impact that brought the original Black Beauty stone here. A minuscule zircon grain inside one of these meteorites, studied for the first time in 2022, provided clues about Mars's early crust formation and preserved evidence of past meteorite impacts. Cavosie said these meteorites offer valuable clues to reconstruct Mars's geological history. Element patterns hint at Mars's early history The research team studied the Martian zircon grain's trace elements to gain insight into its early history. Researchers used nano-scale geochemistry to uncover evidence of hot water on Mars 4.45 billion years ago. They also detected element patterns in zircon, like sodium, iron, yttrium, as well as aluminum. These patterns revealed that these elements were incorporated into the grain as it grew. "Hydrothermal systems were essential for life on Earth and our findings suggest Mars also had water," Cavosie said.

Martin O'Malley joins The LeadJimmy Carter, Former U.S. President and Nobel Peace Prize Winner, Dies at 100Mutual of America Capital Management LLC Sells 4,719 Shares of Sensata Technologies Holding plc (NYSE:ST)